Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study

Clinical pharmacology, efficacy and safety of atazanavir: a review

(2009) Danièle Bentué-Ferrer et al.   Expert Opinion on Drug Metabolism & Toxicology

Vascular risk screening: possible or too much, too soon?

(2009) A. S. Wierzbicki et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Epidemiological Evidence for Cardiovascular Disease in HIV-Infected Patients and Relationship to Highly Active Antiretroviral Therapy

(2008) Judith S. Currier et al.   CIRCULATION

HIV lipodystrophy and its metabolic consequences: implications for clinical practice

(2008) Anthony S. Wierzbicki et al.   CURRENT MEDICAL RESEARCH AND OPINION

Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen

(2008) M Colafigli et al.   HIV MEDICINE

Estimated 10-year cardiovascular risk in a British population: results of a national screening project

(2008) H. A. W. Neil et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: Results from the SIMONE study

(2008) Giuseppe Vittorio L. De Socio et al.   JOURNAL OF INFECTION

Guidelines for managing cardiovascular risk: an evolving area

(2008) Judith S Currier et al.   Current Opinion in HIV and AIDS